Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...